Hepatitis B virus (HBV)-related
acute-on-chronic liver failure (ACLF) has a poor prognosis with high in-hospital mortality. Hepatic and circulating inflammatory
cytokines, such as
fibrinogen like
protein 2 (fgl2), FasL/Fas, and TNFα/
TNFR1, play a significant role in the pathophysiology of ACLF. This study aimed to investigate the
therapeutic effect of recombinant adenoviral vectors carrying constructed
DNA code for non-native
microRNA (
miRNA) targeting mouse fgl2 (mfgl2) or both mFas and mTNFR1 on murine hepatitis virus (MHV)-3-induced
fulminant hepatitis in BALB/cJ mice. Artificial
miRNA eukaryotic expression plasmids against mfgl2, mFas, and mTNFR1 were constructed, and their inhibitory effects on the target genes were confirmed in vitro. pcDNA6.2-mFas-mTNFR1- miRNA,which expresses
miRNA against both mFas and mTNFR1 simultaneously,was constructed. To construct a
miRNA adenovirus expression vector against mfgl2, pcDNA6.2-mfgl2-miRNA was cloned using Gateway technology. Ad-mFas-mTNFR1-
miRNA was also constructed by the same procedure. Adenovirus vectors were delivered by tail-vein injection into MHV-3-infected BALB/cJ mice to evaluate the
therapeutic effect. 8 of 18 (44.4%) mice recovered from fulminant viral
hepatitis in the combined interference group treated with Ad-mfgl2-miRNA and Ad-mFas-mTNFR1-miRNA. But only 4 of 18 (22.2%) mice receiving Ad-mfgl2-miRNA and 3 of 18 (16.7%) mice receiving Ad-mFas-mTNFR1-
miRNA survived. These adenovirus vectors significantly ameliorated inflammatory infiltration,
fibrin deposition, hepatocyte
necrosis and apoptosis, and prolonged survival time. Our data illustrated that combined interference using adenovirus-mediated artificial
miRNAs targeting mfgl2, mFas, and mTNFR1 might have significant therapeutic potential for the treatment of
fulminant hepatitis.